Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclosporine ophthalmic solution
- Development stage
- Approved
- Lead developer
- Harrow
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
Cyclosporine ophthalmic solution is a topical immunosuppressant used in the treatment of ocular surface diseases. It acts as a calcineurin inhibitor that blocks T cell activation and reduces ocular inflammation. This mechanism increases tear production in patients with keratoconjunctivitis sicca (dry eye disease) and helps treat other inflammatory conditions of the eye such as vernal keratoconjunctivitis. Cyclosporine also improves goblet cell density and has anti-apoptotic properties on the ocular surface. The drug is formulated to address its poor aqueous solubility through emulsions or nanomicellar solutions for better bioavailability and tolerability[3][6][7][8].
- Brand names
- CequaRestasisVerkaziaVevyeKlarity-C
- Other names
- cyclosporine ophthalmic emulsioncyclosporine eye drops
02
Targets
CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)PPIF (Cyclophilin D)
Beyond the preview
Go deeper on cyclosporine ophthalmic solution.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclosporine ophthalmic solution.